Demographic and clinical characteristics of cardiac surgery patients developing TRALI and control patients
| . | Transfused groups . | Nontransfused group: no ALI (n = 32) . | |
|---|---|---|---|
| TRALI (n = 16) . | No ALI (n = 32) . | ||
| Age, y (SD) | 74 (7.4)* | 67 (9.3)† | 63 (13)§ |
| Male sex, n (%) | 12 (75) | 20 (63) | 28 (88) |
| EUROscore, mean (SD) | 6.4 (2.8) | 5.8 (3.3) | 3.9 (2.4)§ |
| ASA, mean (SD) | 3.3 (0.5) | 3.1 (0.5) | 2.7 (0.6)‖ |
| Medical history | |||
| Alcohol abuse, n (%) | 1 (6) | 2 (6) | 0 (0) |
| Smoking, n (%) | 2 (13) | 9 (28) | 9 (28) |
| Myocardial infarction, n (%) | 2 (13) | 11 (34) | 10 (31) |
| Hypertension, n (%) | 8 (50) | 24 (75) | 17 (53) |
| Diabetes, n (%) | 4 (25) | 12 (38) | 3 (9) |
| Vascular diseases, n (%) | 3 (19) | 10 (31) | 3 (9) |
| Malignancy, n (%) | 1 (6) | 3 (9) | 0 (0) |
| CVA, n (%) | 3 (19) | 1 (3) | 2 (6) |
| Autoimmune, n (%) | 1 (6) | 2 (6) | 9 (28)* |
| % predictive vital capacity, mean (SD) | 90 (31) | 98 (15) | 103 (18) |
| % predictive FEV1, mean (SD) | 79 (31) | 88 (17) | 98 (21) |
| Left ventricular function | |||
| Poor | 1 (6) | 5 (16) | 1 (3) |
| Moderate | 7 (44) | 5 (16) | 7 (22) |
| Good | 8 (50) | 22 (69) | 22 (69) |
| Preoperative | |||
| Mean hemoglobin, mM, (SD) | 8.8 (1.0) | 8.5 (0.8) | 9.2 (0.8) |
| Median PLT count, × 109, (IQR) | 213 (176-249) | 249 (209-290) | 231 (197-260) |
| Median leukocyte count, × 106, (IQR) | 7.8 (5.6-9.9) | 7.8 (6.6-9.6) | 7.0 (6.2-8.7) |
| Mean urea, mM, (SD) | 7.4 (2.5) | 6.8 (2.6) | 6.4 (1.5) |
| Mean creatinine, mM, (SD) | 93 (25) | 85 (23) | 83 (15) |
| Mean INR, (SD) | 1.1 (0.2) | 1.1 (0.3) | 1.2 (0.8) |
| Type of surgery | |||
| CABG, n (%) | 6 (38) | 15 (47) | 19 (60) |
| Valve replacement, n (%) | 9 (56) | 16 (50) | 9 (28) |
| Bentall, n (%) | 1 (6) | 0 (0) | 2 (6) |
| Other, n (%) | 0 (0) | 1 (3) | 2 (6) |
| Perioperative | |||
| Median clamp time, min (IQR) | 101 (86-146)§ | 75 (62-100)‡ | 74 (46-94)§ |
| Median pump time, min (IQR) | 170 (126-198)* | 117 (90-147)† | 110 (78-131)‖ |
| Mean total surgery time, min (IQR) | 359 (273-416)* | 249 (300-450)† | 235 (200-266)‖ |
| Dexamethasone, n (%) | 6 (38) | 3 (9) | 9 (28) |
| Opioid use, n (%) | 16 (100) | 32 (100) | 32 (100) |
| . | Transfused groups . | Nontransfused group: no ALI (n = 32) . | |
|---|---|---|---|
| TRALI (n = 16) . | No ALI (n = 32) . | ||
| Age, y (SD) | 74 (7.4)* | 67 (9.3)† | 63 (13)§ |
| Male sex, n (%) | 12 (75) | 20 (63) | 28 (88) |
| EUROscore, mean (SD) | 6.4 (2.8) | 5.8 (3.3) | 3.9 (2.4)§ |
| ASA, mean (SD) | 3.3 (0.5) | 3.1 (0.5) | 2.7 (0.6)‖ |
| Medical history | |||
| Alcohol abuse, n (%) | 1 (6) | 2 (6) | 0 (0) |
| Smoking, n (%) | 2 (13) | 9 (28) | 9 (28) |
| Myocardial infarction, n (%) | 2 (13) | 11 (34) | 10 (31) |
| Hypertension, n (%) | 8 (50) | 24 (75) | 17 (53) |
| Diabetes, n (%) | 4 (25) | 12 (38) | 3 (9) |
| Vascular diseases, n (%) | 3 (19) | 10 (31) | 3 (9) |
| Malignancy, n (%) | 1 (6) | 3 (9) | 0 (0) |
| CVA, n (%) | 3 (19) | 1 (3) | 2 (6) |
| Autoimmune, n (%) | 1 (6) | 2 (6) | 9 (28)* |
| % predictive vital capacity, mean (SD) | 90 (31) | 98 (15) | 103 (18) |
| % predictive FEV1, mean (SD) | 79 (31) | 88 (17) | 98 (21) |
| Left ventricular function | |||
| Poor | 1 (6) | 5 (16) | 1 (3) |
| Moderate | 7 (44) | 5 (16) | 7 (22) |
| Good | 8 (50) | 22 (69) | 22 (69) |
| Preoperative | |||
| Mean hemoglobin, mM, (SD) | 8.8 (1.0) | 8.5 (0.8) | 9.2 (0.8) |
| Median PLT count, × 109, (IQR) | 213 (176-249) | 249 (209-290) | 231 (197-260) |
| Median leukocyte count, × 106, (IQR) | 7.8 (5.6-9.9) | 7.8 (6.6-9.6) | 7.0 (6.2-8.7) |
| Mean urea, mM, (SD) | 7.4 (2.5) | 6.8 (2.6) | 6.4 (1.5) |
| Mean creatinine, mM, (SD) | 93 (25) | 85 (23) | 83 (15) |
| Mean INR, (SD) | 1.1 (0.2) | 1.1 (0.3) | 1.2 (0.8) |
| Type of surgery | |||
| CABG, n (%) | 6 (38) | 15 (47) | 19 (60) |
| Valve replacement, n (%) | 9 (56) | 16 (50) | 9 (28) |
| Bentall, n (%) | 1 (6) | 0 (0) | 2 (6) |
| Other, n (%) | 0 (0) | 1 (3) | 2 (6) |
| Perioperative | |||
| Median clamp time, min (IQR) | 101 (86-146)§ | 75 (62-100)‡ | 74 (46-94)§ |
| Median pump time, min (IQR) | 170 (126-198)* | 117 (90-147)† | 110 (78-131)‖ |
| Mean total surgery time, min (IQR) | 359 (273-416)* | 249 (300-450)† | 235 (200-266)‖ |
| Dexamethasone, n (%) | 6 (38) | 3 (9) | 9 (28) |
| Opioid use, n (%) | 16 (100) | 32 (100) | 32 (100) |
CVA indicates cerebrovascular accident; FEV1, forced expiratory volume in 1 second; IQR, interquartile range; INR, international normalized ratio; and CABG, coronary artery bypass graft.
P < .05, TRALI vs transfused or nontransfused controls.
P < .05, transfused controls vs nontransfused controls.
P < .01, transfused controls vs nontransfused controls.
P < .01,TRALI vs transfused or nontransfused controls.
P < .001, TRALI vs transfused or nontransfused controls.